The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Anemia of Chronic Disease: Detailed Pathophysiology and Management

Hepcidin-mediated iron-restricted anemia in inflammatory disorders with targeted treatment approaches

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Anemia of Chronic Disease: Detailed Pathophysiology and Management?

Anemia of chronic disease results from inflammation-driven dysregulation of iron homeostasis with hepcidin-mediated reduction in iron absorption and macrophage iron release.

Pathophysiologic features include functional iron deficiency, suppressed erythropoietin response and reduced red cell survival mediated by inflammatory cytokines.

Common underlying conditions include rheumatologic diseases, chronic infections, malignancies, chronic kidney disease and inflammatory bowel disease.

Laboratory features include normochromic normocytic anemia, low or normal serum iron with normal or elevated ferritin, low transferrin saturation and elevated inflammatory markers.

Differential diagnosis from iron deficiency anemia is critical and may require ferritin, transferrin saturation, soluble transferrin receptor and bone marrow examination.

Symptoms

Fatigue, weakness and decreased exercise tolerance reflecting underlying anemia.
Symptoms of underlying chronic disease often dominating clinical picture.
Pallor of skin and mucous membranes proportionate to anemia severity.
Cardiovascular symptoms in severe anemia or cardiovascular comorbidities including dyspnea, palpitations and angina.
Anemia typically mild to moderate with hemoglobin between 8 to 11 g/dL though more severe forms occur.

Risk Factors

Active rheumatologic disease including rheumatoid arthritis, lupus, vasculitis and other connective tissue disorders.
Chronic infections including tuberculosis, HIV, osteomyelitis and chronic bacterial or fungal infections.
Malignancies particularly metastatic cancer and hematologic malignancies.
Chronic kidney disease with reduced erythropoietin production compounding inflammation effects.
Inflammatory bowel disease, chronic liver disease and other chronic inflammatory conditions.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent anemia despite treatment of suspected iron deficiency or unclear etiology warrants comprehensive evaluation.
  • Anemia in patient with known chronic inflammatory, infectious or malignant disease requires specialty consultation for combined management.
  • Severe anemia (hemoglobin below 8 g/dL) with symptoms of cardiac decompensation needs urgent evaluation.
  • Failed response to iron therapy in suspected iron deficiency suggests reconsideration of diagnosis with anemia of chronic disease evaluation.
  • Long-term hematologic monitoring is essential during chronic disease management to detect anemia development and response to treatment.

Treatment Methods

01
Treatment of underlying inflammatory, infectious or malignant disease often improves anemia and is the primary therapeutic approach.
02
Erythropoiesis-stimulating agents including epoetin alfa and darbepoetin are options for selected patients with chronic kidney disease, cancer chemotherapy or persistent anemia.
03
Iron therapy with intravenous iron when functional iron deficiency complicates anemia of chronic disease, with avoidance of unnecessary oral iron in pure inflammatory anemia.
04
Targeted therapies for hepcidin-mediated pathways including emerging agents in clinical trials for refractory cases.
05
Comprehensive care addressing underlying disease, monitoring for complications, careful evaluation of mixed iron deficiency components, supportive transfusion therapy when indicated and management of cardiovascular risk factors optimize outcomes in this prevalent condition.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.